ArticlePharmacoEconomics2011
Cost estimation of cardiovascular disease events in the US.
Article in PharmacoEconomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Cost-Effectiveness of Two Iterations of a Community-Based Cardiovascular Disease Prevention Intervention.Obesity (Silver Spring, Md.) · 2026Trial
- Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.PharmacoEconomics · 2013Trial
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.PharmacoEconomics · 2026Article
- A Model to Assess the Costs and Consequences of Changes in Diet and Nutrition From Potential Population-Wide Policies: The Microsimulation of Nutrition, Diabetes, and Cardiovascular Disease (MONDAC).Preventing chronic disease · 2025Article
- Changes in urine albumin-to-creatinine ratio and health care resource utilization and costs in patients with type 2 diabetes and chronic kidney disease.Journal of managed care & specialty pharmacy · 2025Article
- Delayed or forgone medical care associated with increased resource utilization and health care expenditures among patients with peripheral artery disease in the United States.Journal of vascular surgery · 2025Article
- Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.Journal of the American Heart Association · 2024Article
- Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis.Annals of internal medicine · 2023Article
- Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program.Frontiers in public health · 2023Article
- Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis.PharmacoEconomics - open · 2023Article
- Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk-Enhancing Factor in the Pooled Cohort Equation: A Cost-Effectiveness Analysis Study.Journal of the American Heart Association · 2022Article
- Food as medicine? Exploring the impact of providing healthy foods on adherence and clinical and economic outcomes.Exploratory research in clinical and social pharmacy · 2022Article
- Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2022Article
- Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.Surgery · 2022Article
- Article
- Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases.Health care management science · 2021Article
- Article
- Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.JAMA cardiology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we developed cost prediction equations that facilitate estimation of the costs of various cardiovascular events for patients of specific demographic and clinical characteristics over varying time horizons.
methodsWe used administrative claims data and generalized linear models to develop cost prediction equations for selected cardiovascular events, including myocardial infarction (MI), angina, strokes and revascularization procedures. Separate equations were estimated for patients with events and for their propensity score-matched controls. Attributable costs were estimated on a monthly basis for the first 36 months after each event and annually thereafter, with differences in survival between cases and controls factored into the longitudinal cost calculations. The regression models were used to estimate event costs ($US, year 2007 values) for the 'average' patient in each event group, over various time periods ranging from 1 month to lifetime.
resultsWhen the equations are run for the average patient in each event group, attributable costs of each event in the acute phase (i.e. first 3 years) are substantial (e.g. MI $US 73 300; hospitalization for angina $US 36 000; non-fatal haemorrhagic stroke $US 71 600). Furthermore, for most events, cumulative costs remain substantially higher among cases than among controls over the remaining lifetime of the patients.
conclusionsThis study provides updated estimates of medical care costs of cardiovascular events among a managed care population over various time horizons. Results suggest that the economic burden of cardiovascular disease is substantial, both in the acute phase as well as over the longer term.
Indexed as
Identifiers
21585226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.